US2013245011A1PendingUtilityA1
Modulators of ATP-Binding Cassette Transporters
Est. expiryNov 8, 2025(expired)· nominal 20-yr term from priority
Inventors:Sara S. Hadida RuahMatthew HamiltonMark MillerPeter D.J. GrootenhuisBrian BearJason MccartneyJinglan Zhou
A61P 43/00A61P 5/16A61P 3/06A61P 5/00A61P 3/10A61P 7/12A61P 7/02A61P 5/14A61P 5/50A61P 3/08A61P 5/18A61P 7/00A61P 9/00A61P 35/00A61P 27/04A61P 25/16A61P 25/28A61P 25/14A61P 27/02A61P 3/00A61P 25/00A61P 21/04A61P 19/04A61P 17/00A61P 11/00A61P 19/08A61P 21/02A61P 13/00A61P 1/00A61P 21/00A61P 19/00A61P 13/02A61P 13/12C07D 317/12A61K 31/496C07D 405/12A61K 31/5377A61K 31/4545G01N 33/6872A61K 31/497A61K 31/47A61K 31/506A61K 45/06C07D 405/14A61K 31/444C07K 14/4712A61K 31/4525A61K 31/443A61K 31/4709A61K 31/501
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Claims
exact text as granted — not AI-modified1 . A compound of formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
Each R 1 is an optionally substituted C 1-6 aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3-10 cycloaliphatic, an optionally substituted 3 to 10 membered heterocycloaliphatic, carboxy, amido, amino, halo, or hydroxy, provided that at least one R 1 is an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl attached to the 5- or 6-position of the pyridyl ring;
Each R 2 is hydrogen, an optionally substituted C 1-6 aliphatic, an optionally substituted C 3-6 cycloaliphatic, an optionally substituted phenyl, or an optionally substituted heteroaryl;
Each R 3 and R′ 3 together with the carbon atom to which they are attached form an optionally substituted C 3-7 cycloaliphatic or an optionally substituted heterocycloaliphatic;
Each R 4 is an optionally substituted aryl or an optionally substituted heteroaryl; and
Each n is 1, 2, 3 or 4.
2 . The compound according to claim 1 , wherein one R 1 that is attached to 5- or 6-position of the pyridyl ring is aryl or heteroaryl, each optionally substituted with 1, 2, or 3 of R D ; wherein R D is —Z D R 9 ; wherein each Z D is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —CO—, —CS—, —CONR E —, —CONR E NR E —, —CO 2 —, —OCO—, —NR E CO 2 —, —O—, —NR E CONR E —, —OCONR E —, —NR E NR E —, —NR E CO—, —S—, —SO—, —SO 2 —, —NR E —, —SO 2 NR E —, —NR E SO 2 —, or —NR E SO 2 NR E —; each R 9 is independently R E , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ; and each R E is independently hydrogen, an optionally substituted C 1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.
3 . The compound according to claim 2 , wherein the one R 1 attached to the 5- or 6-position of the pyridyl ring is phenyl optionally substituted with 1, 2, or 3 of R D .
4 . The compound according to claim 2 , wherein the one R 1 attached to the 5- or 6-position of the pyridyl ring is heteroaryl optionally substituted with 1, 2, or 3 of R D .
5 . The compound according to claim 2 , wherein one R 1 attached to the 5- or 6-position of the pyridyl ring is a 5 or 6 membered heteroaryl having 1, 2, or 3 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with 1 of R D , wherein R D is —Z D R 9 ; each Z D is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —O—, —NHC(O)—, —C(O)NR E —, —SO 2 —, —NHSO 2 —, —NHC(O)—, —NR E SO 2-5 —SO 2 NH—, —SO 2 NR E —, —NH—, or —C(O)O—.
6 . The compound according to claim 5 , wherein one carbon unit of Z D is replaced by —O—, —NHC(O)—, —C(O)NR E —, —SO 2 —, —NHSO 2 —, —NHC(O)—, —SO—, —NR E SO 2 —, —SO 2 NH—, —SO 2 NR E —, —NH—, or —C(O)O—.
7 . The compound according to claim 2 , wherein R 9 is independently an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl, H, or halo.
8 . The compound according to claim 1 , wherein one R 1 that is attached to the 5- or 6-position of the pyridyl ring is cycloaliphatic or heterocycloaliphatic, each optionally substituted with 1, 2, or 3 of R D .
9 . The compound according to claim 8 , wherein one R 1 that is attached to the 5- or 6-position of the pyridyl ring is an optionally substituted C 3 -C 8 cycloalkyl or an optionally substituted C 3 -C 8 cycloalkenyl.
10 . The compound according to claim 1 , wherein the one R 1 attached to the 5- or 6-position of the pyridyl ring is selected from the group consisting of
11 . The compound according to claim 1 , wherein R 2 is hydrogen.
12 . The compound according to claim 1 , wherein R 3 and R′ 3 together with the carbon atom to which they are attached form an unsubstituted C 3-7 cycloaliphatic or an unsubstituted heterocycloaliphatic.
13 . The compound according to claim 12 , wherein R 3 and R′ 3 together with the carbon atom to which they are attached form an unsubstituted cyclopropyl, an unsubstituted cyclopentyl, or an unsubstituted cyclohexyl.
14 . The compound according to claim 1 , wherein R 4 is an aryl or heteroaryl optionally substituted with 1, 2, or 3 of —Z C R 8 , wherein each Z C is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C —, —NR C CO—, —S—, —SO—, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, or —NR C SO 2 NR C —; each R 8 is independently R C , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 ; and each R C is independently an optionally substituted C 1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.
15 . The compound according to claim 14 , wherein R 4 is an aryl optionally substituted with 1, 2, or 3 of —Z C R 8 .
16 . The compound according to claim 15 , wherein R 4 is an optionally substituted phenyl.
17 . The compound according to claim 14 , wherein R 4 is a heteroaryl optionally substituted with 1, 2, or 3 of —Z C R 8 .
18 . The compound according to claim 14 , wherein R 4 is one selected from
19 . The compound according to claim 1 , wherein said compound has formula (IV):
or a pharmaceutically acceptable salt thereof, wherein
R D is —Z D R 9 , wherein each Z D is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —CO—, —CS—, —CONR E —, —CONR E NR E —, —CO 2 —, —OCO—, —NR E CO 2 —, —O—, —NR E CONR E —, —OCONR E —, —NR E NR E —, —NR E CO—, —S—, —SO—, —SO 2 —, —NR E —, —SO 2 NR E —, —NR E SO 2 —, or —NR E SO 2 NR E —;
R 9 is independently R E , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ;
Each R E is independently hydrogen, an optionally substituted C 1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
R 2 is C 1-4 aliphatic, C 3-6 cycloaliphatic, phenyl, or heteroaryl, each of which is optionally substituted, or R 2 is hydrogen;
R 3 and R′ 3 together with the carbon atom to which they are attached form a C 3-7 cycloaliphatic or a C 3-7 heterocycloaliphatic, each of which is optionally substituted with 1, 2, or 3 of —Z B R 7 , wherein each Z B is independently a bond, or an optionally substituted branched or straight C 1-4 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B —, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, or —NR B SO 2 NR B —;
Each R 7 is independently R B , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ;
Each R B is independently hydrogen, an optionally substituted C 1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;
Each R 4 is an aryl or heteroaryl, each of which is optionally substituted with 1, 2, or 3 of —Z C R 8 , wherein each Z C is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C —, —NR C CO—, —S—, —SO—, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, or —NR C SO 2 NR C —;
Each R 8 is independently R C , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ; and
Each R C is independently an optionally substituted C 1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.
20 . The compound according to claim 19 , wherein said compound has formula V-A or formula V-B:
or a pharmaceutically acceptable salt thereof,
wherein:
T is an optionally substituted C 1-2 aliphatic chain, wherein each of the carbon units is optionally and independently replaced by —CO—, —CS—, —COCO—, —SO 2 —, —B(OH)—, or —B(O(C 1-6 alkyl))-;
Each of R 1 ′ and R 1 ″ is an optionally substituted C 1-6 aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted 3 to 10 membered cycloaliphatic, an optionally substituted 3 to 10 membered heterocycloaliphatic, carboxy, amido, amino, halo, or hydroxy;
R D1 is attached to carbon number 3″ or 4″;
each R D1 and R D2 is —Z D R 9 , wherein each Z D is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —CO—, —CS—, —CONR E —, —CONR E NR E —, —CO 2 —, —OCO—, —NR E CO 2 —, —O—, —NR E CONR E —, —OCONR E —, —NR E NR E —, —NR E CO—, —S—, —SO—, —SO 2 —, —NR E —, —SO 2 NR E —, —NR E SO 2 —, or —NR E SO 2 NR E —;
R 9 is independently R E , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ;
or R D1 and R D2 , taken together with atoms to which they are attached, form a 3-8 membered saturated, partially unsaturated, or aromatic ring with up to 3 ring members independently selected from the group consisting of O, NH, NR E , and S; and
each R E is independently hydrogen, an optionally substituted C 1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.
21 . The compound according to claim 20 , wherein up to two methylene units of T are independently and optionally replaced by —CO—, —CS—, —B(OH), or —B(O(C 1-6 alkyl).
22 . The compound according to claim 20 , wherein T is an optionally substituted chain selected from the group consisting of —CH 2 — and —CH 2 CH 2 —.
23 . The compound according to claim 20 , wherein T is optionally substituted by F, Cl, C 1-6 alkyl, C 3-8 cycloalkyl, phenyl, naphthyl, —O—(C 1-6 alkyl), —O—(C 3-8 cycloalkyl), —O-phenyl, or C 3-8 spiroaliphatic.
24 . The compound according to claim 20 , wherein T is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CF 2 —, —C(CH 3 ) 2 —, —C(O)—,
C(Phenyl) 2 -, —B(OH)—, and —CH(OEt)-.
25 . The compound according to claim 24 , wherein T is selected from the group consisting of —CH 2 —, —CF 2 —, and —C(CH 3 ) 2 —.
26 . The compound according to claim 20 , wherein Z D is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein one carbon unit of Z D is optionally replaced by —CO—, —SO—, —SO 2 —, —COO—, —OCO—, —CONR E —, —NR E CO—, NR E CO 2 —, —O—, —NR E SO 2 —, or —SO 2 NR E —.
27 . The compound according to claim 20 , wherein R D1 is —Z D R 9 , wherein R 9 is halo, —OH, —NH 2 , —CN, —CF 3 , —OCF 3 , or an optionally substituted group selected from the group consisting of C 1-6 aliphatic, C 3-8 cycloaliphatic, 3-8 membered heterocycloaliphatic, C 6-10 aryl, and 5-10 membered heteroaryl.
28 . The compound according to claim 27 , wherein R 9 is F, Cl, —OH, —CN, —CF 3 , or —OCF 3 .
29 . The compound according to claim 27 , wherein R 9 is selected from the group consisting of C 1-6 straight or branched alkyl or C 2-6 straight or branched alkenyl; wherein said alkyl or alkenyl is optionally substituted by 1 or 2 substituents independently selected from the group consisting of R E , oxo, halo, —OH, —NR E R E , —OR E , —COOR E , and —CONR E R E .
30 . The compound according to claim 27 , wherein R 9 is C 3-8 cycloaliphatic optionally substituted by 1 or 2 substituents independently selected from the group consisting of R E , oxo, halo, —OH, —NR E R E , —OR E , —COOR E , and —CONR E R E .
31 . The compound according to claim 30 , wherein R 9 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
32 . The compound according to claim 27 , wherein R 9 is a 3-8 membered heterocyclic with 1 or 2 heteroatoms independently selected from the group consisting of O, NH, NR E , and S; wherein said heterocyclic is optionally substituted by 1 or 2 substituents independently selected from the group R E , oxo, halo, —OH, —NR E R E , —OR E , —COOR E , and —CONR E R E .
33 . The compound according to claim 32 , wherein R 9 is an optionally substituted 3-8 membered heterocyclic is
34 . The compound according to claim 32 , wherein R 9 is optionally substituted by 1 or 2 substituents independently selected from the group consisting of oxo, F, Cl, methyl, ethyl, i-propyl, t-butyl, —CH 2 OH, —CH 2 CH 2 OH, —C(O)OH, —C(O)NH 2 , —CH 2 O(C 1-6 alkyl), —CH 2 CH 2 O(C 1-6 alkyl), and —C(O)(C 1-6 alkyl).
35 . The compound according to claim 27 , wherein R 9 is 5-8 membered heteroaryl with 1 or two ring atom independently selected from the group consisting of O, S, and NR E ; wherein said heteroaryl is optionally substituted by 1 or 2 substituents independently selected from the group R E , oxo, halo, —OH, —NR E R E , —OR E , —COOR E , and —CONR E R E .
36 . The compound according to claim 35 , wherein R 9 is
37 . The compound according to claim 35 , wherein R 9 is optionally substituted by 1 or 2 substituents independently selected from the group consisting of F, Cl, methyl, ethyl, i-propyl, t-butyl, —CH 2 OH, —CH 2 CH 2 OH, —C(O)OH, —C(O)NH 2 , —CH 2 O(C 1-6 alkyl), —CH 2 CH 2 O(C 1-6 alkyl), and —C(O)(C 1-6 alkyl).
38 . The compound according to claim 20 , wherein R D1 and R D2 , taken together with carbons to which they are attached, form an optionally substituted 3-8 membered saturated, partially unsaturated, or aromatic ring with 0-2 ring atoms independently selected from the group consisting of O, NH, NR E , and S.
39 . The compound according to claim 38 , wherein R D1 and R D2 , taken together with phenyl containing carbon atoms 3″ and 4″, is
40 . The compound according to claim 38 , wherein R D1 and R D2 , taken together with phenyl containing carbon atoms 3″ and 4″, is optionally substituted by 1 or 2 substituents independently selected from the group consisting of R E , oxo, halo, —OH, —NR E R E , —OR E , —COOR E , and —CONR E R E .
41 . The compound according to claim 20 , wherein R D2 is selected from the group consisting of H, C 1-6 aliphatic, halo, —CN, —NH 2 , —CH 2 NH 2 , —OH, —O(C 1-6 aliphatic), —CH 2 OH, —SO 2 (C 1-6 aliphatic), —NH—SO 2 (C 1-6 aliphatic), —C(O)O(C 1-6 aliphatic), —C(O)OH, —NHC(O)(C 1-6 aliphatic), —C(O)NH 2 , —C(O)NH(C 1-6 aliphatic), and —C(O)N(C 1-6 aliphatic) 2 .
42 . The compound according to claim 20 , wherein R 1 ″ is hydrogen.
43 . The compound according to claim 20 , wherein R 1 ′ and R 1 ″ are both hydrogen.
44 . The compound according to claim 1 , wherein the compound is selected from
45 . A pharmaceutical composition comprising:
(i) a compound according to claim 1 ; and (ii) a pharmaceutically acceptable carrier.
46 . The composition according to claim 45 , further comprising a mucolytic agent, a bronchodialator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator, or a nutritional agent.
47 - 52 . (canceled)
53 . The composition according to claim 45 , further comprising a CFTR modulator.Join the waitlist — get patent alerts
Track US2013245011A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.